Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), results that can give the red-hot PD-(L)1xVEGF bispecific ...

HONG KONG, Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ...

MIAMI, November 07, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today noted that our partner, Akeso, Inc ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced results from the Phase III HARMONi trial ...

On November 7, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced results from the Phase III HARMONi trial conducted in China. The results were published by its partner Akeso, Inc. The study ...

Summit Therapeutics has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial. New ...

Los Angeles-based eharmony launched in the United States in 2000 with its patented Compatibility Matching System® which allows eharmony members to be matched with compatible persons with whom they are ...

7 Kasım (Reuters) - Teknoloji şirketlerinin ağırlıkta olduğu, yüksek, dalgalı hisse piyasalarındaki ani düşüşten, ABD'de ödeneksiz kalan hükümetin faaliyetlerini durdurmasına kadar gelecek hafta ...

What is the best graphics card? Finding a new gaming GPU can mean navigating a confusing mass of numbers in specs lists, as well as weighing up the pros and cons of the different features available ...

Risk Açıklaması: Finansal araçlar ve/veya kripto paralarla işlem yapmak yüksek seviyede risk içermektedir ve yatırım miktarınızın bir kısmını veya tamamını kaybetmenize sebep olabilir, bu sebeple tüm ...